Show simple item record

dc.contributor.authorShinde, Prajakta
dc.contributor.authorStamatos, Nicholas
dc.contributor.authorDoub, James B
dc.date.accessioned2022-05-09T15:32:17Z
dc.date.available2022-05-09T15:32:17Z
dc.date.issued2022-04-03
dc.identifier.urihttp://hdl.handle.net/10713/18801
dc.description.abstractBacteriophage therapy has been regaining interest as a potential therapeutic in treating a wide range of infections. However, there is a paucity of knowledge regarding numerous aspects of bacteriophage therapy, thereby hindering the development of proper treatment protocols and effective clinical trials. In this report, the activities of three bacteriophages are evaluated against clinical bacterial isolates in the presence and absence of human plasma (HP). The bacteriophages used in this experiment were residual therapeutic doses from the United States Food and Drug Administration (FDA) approved compassionate use cases to treat recalcitrant prosthetic joint infections (PJIs). Herein we demonstrate that in the presence of HP, the infectivity of these Staphylococcal bacteriophages was significantly reduced compared to the infectivity in the absence of HP. Inhibition of infectivity ranged from 48% to 81% for two methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates independently infected with the same bacteriophage and 98% for a third MRSA clinical isolate infected with a different bacteriophage. In contrast, bacteriophage infectivity of an Enterococcus faecalis clinical isolate was not affected by the presence of HP. We hypothesize that the inhibition is correlated with plasma proteins binding to Staphylococcal surface proteins masking the receptors associated with bacteriophage attachment, thereby reducing infectivity. This has clinical ramifications for bacteriophage therapy use in treating Staphylococcal bacteremia and periprosthetic joint infections.en_US
dc.description.urihttps://doi.org/10.7759/cureus.23777en_US
dc.language.isoenen_US
dc.publisherCureus, Inc.en_US
dc.relation.ispartofCureusen_US
dc.rightsCopyright © 2022, Shinde et al.en_US
dc.subjectbacteremiaen_US
dc.subjectbacteriophage therapyen_US
dc.subjectperiprosthetic joint infectionen_US
dc.subjectplasma proteinsen_US
dc.subjectstaphylococcus aureusen_US
dc.titleHuman Plasma Significantly Reduces Bacteriophage Infectivity Against Staphylococcus aureus Clinical Isolates.en_US
dc.typeArticleen_US
dc.identifier.doi10.7759/cureus.23777
dc.identifier.pmid35509731
dc.source.journaltitleCureus
dc.source.volume14
dc.source.issue4
dc.source.beginpagee23777
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record